Drug treatment of multiple sclerosis

British Medical Journal

Volumn 321, Issue 7259, 2000, Pages 490-494

  Polman, C H ^a   Uitdehaag, B M J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; PREDNISONE; RECOMBINANT BETA INTERFERON;

DISEASE COURSE; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RELAPSE; SHORT SURVEY;

CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSION; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 0034686907     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (27)

1. 1 Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995;119:119-46.
2. 2 Oksenberg JR, Hauuser SL. New insights into the immunogenetics of multiple sclerosis. Curr Opin Neurol 1997;10:181-5.
3. 3 Lucchinetti CF, Bruck W, Rodriguez M, Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 1996;6:259-74.
4. 4 Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
5. 5 Miller DH, Grossman RI, Reingold SC, McFarland HF. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24.
6. 6 Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997;349:902-6.
7. 7 Uitdehaag BMJ, Barkhof F. Methylprednisolone for acute relapses of multiple sclerosis. Can oral replace intravenous administration? CNS Drugs 1998;10:233-8.
8. 8 Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
9. 9 The PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised, double-blind, placebo-controlled study of interferon β1a in relapsing/ remitting multiple sclerosis. Lancet 1998;352:1498-1504.
10. 10 The IFNB Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-bind, placebo-controlled trial. Neurology 1993;43:655-61.
11. 11 Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology 1995;45:1268-76.
12. 12 Paty DW, Li DKB, the UBC MS/MRI Study Group, the Interferon Beta Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-bind, placebo-controlled trial. Neurology 1993;43:662-7.
13. 13 Li DKB, Paty DW, the UBC MS/MHI Analysis Research Group, the PRISMS Study Group. Magnetic resonance imaging results of the PRISMS trial: a randomised, double-blind, placebo-controlled study of interferon-β1a in relapsing-remitting multiple sclerosis. Ann Neurol 1999;46:197-206.
14. 14 Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing remitting multiple sclerosis. Ann Neurol 1998;43:79-87.
15. 15 Comi G, Barkhof F, Durelli L, Edan G, Fernandez O, Filippi M, et al. Early treatment of multiple sclerosis with Rebif (recombinant human interferon beta): design of the study. Multiple Sclerosis 1995;1:24-7S.
16. 16 The Once Weekly Interferon for Multiple Sclerosis Study Group. Evidence of interferon β-1a dose response in relapsing-remitting MS. The OWIMS study. Neurology 1999;53:679-86.
17. 17 Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon β: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68:144-9.
18. 18 Comi G, Filippi M, for the Copaxone Magnetic Resonance imaging Study Group. The effect of glatiramer acetate (Copaxone) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-centre, randomized, double-blind, placebo-controlled study extended by open label treatment. Neurology 1999;52 (suppl 2):A289.
19. 19 European Study Group on Interferon beta-1b in secondary-progressive multiple sclerosis. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7.
20. 20 Forbes RB, Lees A, Waught N, Swingler RJ. Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 1999;319:1529-33.
21. 21 Yudkin PL, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, et al. Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-5.
22. 22 Goodkin DE, Rudick RA, VanderBrug Medendorp S, Daughtry MM, Schwetz KM, Fisher J, et al. Low-dose (7.5 mg) oral methotiexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol 1995;37:30-40.
23. 23 Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997;120:865-916.
24. 24 Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in multiple sclerosis lesions. N Engl J Med 1998;338:278-85.
25. 25 Paolillo A, Coles AJ. Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath III. Neurology 1999;53:751-7.
26. 26 Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, et al. Monoclonal antibody treatment exposis three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304.
27. 27 Lucchinetti C, Bruck W, Parisi J. Scheithauer B, Rodriguez M, Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999;122:2279-95.